Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more
Vectus Biosystems Ltd (VBS) - Net Assets
Latest net assets as of June 2025: AU$-256.62K AUD
Based on the latest financial reports, Vectus Biosystems Ltd (VBS) has net assets worth AU$-256.62K AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$782.66K) and total liabilities (AU$1.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-256.62K |
| % of Total Assets | -32.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -106.85% |
| Growth Volatility | 7209.56 |
Vectus Biosystems Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Vectus Biosystems Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vectus Biosystems Ltd (2012–2025)
The table below shows the annual net assets of Vectus Biosystems Ltd from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$-256.62K | -117.27% |
| 2024-06-30 | AU$1.49 Million | -57.82% |
| 2023-06-30 | AU$3.52 Million | +179.69% |
| 2022-06-30 | AU$-4.42 Million | -52.50% |
| 2021-06-30 | AU$-2.90 Million | +56.79% |
| 2020-06-30 | AU$-6.71 Million | -79.91% |
| 2019-06-30 | AU$-3.73 Million | -65.30% |
| 2018-06-30 | AU$-2.26 Million | -2035.78% |
| 2017-06-30 | AU$116.56K | -96.89% |
| 2016-06-30 | AU$3.75 Million | -66.58% |
| 2015-06-30 | AU$11.22 Million | +20101.70% |
| 2014-06-30 | AU$55.53K | -94.31% |
| 2013-06-30 | AU$976.04K | +293.44% |
| 2012-06-30 | AU$-504.57K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vectus Biosystems Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3322142600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$38.37 Million | % |
| Other Comprehensive Income | AU$878.10K | % |
| Other Components | AU$1.00 | % |
| Total Equity | AU$-256.62K | 100.00% |
Vectus Biosystems Ltd Competitors by Market Cap
The table below lists competitors of Vectus Biosystems Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NorCom Information Technology GmbH & Co. KGaA
XETRA:NC5A
|
$2.02 Million |
|
Megalestari Epack Sentosaraya Pt
JK:EPAC
|
$2.02 Million |
|
DF Deutsche Forfait AG
XETRA:DFTK
|
$2.02 Million |
|
AST Groupe
PA:ALAST
|
$2.02 Million |
|
Focus Universal Inc
NASDAQ:FCUV
|
$2.02 Million |
|
PALATIN TECHS DL-01
F:PTN
|
$2.02 Million |
|
Traka Resources Ltd
AU:TKL
|
$2.02 Million |
|
MMEX Resources Corp
PINK:MMEX
|
$2.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vectus Biosystems Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,486,365 to -256,622, a change of -1,742,987 (-117.3%).
- Net loss of 1,777,259 reduced equity.
- Other comprehensive income increased equity by 34,272.
- Other factors decreased equity by 0.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-1.78 Million | -692.56% |
| Other Comprehensive Income | AU$34.27K | +13.36% |
| Total Change | AU$- | -117.27% |
Book Value vs Market Value Analysis
This analysis compares Vectus Biosystems Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-06-30 | AU$-0.03 | AU$0.15 | x |
| 2013-06-30 | AU$0.06 | AU$0.15 | x |
| 2014-06-30 | AU$0.00 | AU$0.15 | x |
| 2015-06-30 | AU$0.79 | AU$0.15 | x |
| 2016-06-30 | AU$0.18 | AU$0.15 | x |
| 2017-06-30 | AU$0.00 | AU$0.15 | x |
| 2018-06-30 | AU$-0.10 | AU$0.15 | x |
| 2019-06-30 | AU$-0.16 | AU$0.15 | x |
| 2020-06-30 | AU$-0.29 | AU$0.15 | x |
| 2021-06-30 | AU$-0.10 | AU$0.15 | x |
| 2022-06-30 | AU$-0.13 | AU$0.15 | x |
| 2023-06-30 | AU$0.07 | AU$0.15 | x |
| 2024-06-30 | AU$0.03 | AU$0.15 | x |
| 2025-06-30 | AU$0.00 | AU$0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vectus Biosystems Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -371.67%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-457.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-1.38 Million |
| 2013 | -126.83% | -187.64% | 0.44x | 1.53x | AU$-1.34 Million |
| 2014 | -2669.02% | -169.92% | 1.21x | 12.93x | AU$-1.49 Million |
| 2015 | -14.76% | -56111.49% | 0.00x | 1.05x | AU$-2.78 Million |
| 2016 | -85.65% | -4277.57% | 0.02x | 1.25x | AU$-3.59 Million |
| 2017 | -3255.11% | -7690.48% | 0.07x | 6.18x | AU$-3.81 Million |
| 2018 | 0.00% | -141614.45% | 0.01x | 0.00x | AU$-2.36 Million |
| 2019 | 0.00% | -725581.82% | 0.00x | 0.00x | AU$-1.22 Million |
| 2020 | 0.00% | -5853.30% | 0.02x | 0.00x | AU$-2.33 Million |
| 2021 | 0.00% | -2145135.56% | 0.00x | 0.00x | AU$-3.57 Million |
| 2022 | 0.00% | -307.19% | 0.33x | 0.00x | AU$-3.55 Million |
| 2023 | -97.88% | -254.62% | 0.29x | 1.31x | AU$-3.80 Million |
| 2024 | -157.30% | -205.34% | 0.56x | 1.36x | AU$-2.49 Million |
| 2025 | 0.00% | -371.67% | 0.61x | 0.00x | AU$-1.75 Million |
Industry Comparison
This section compares Vectus Biosystems Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vectus Biosystems Ltd (VBS) | AU$-256.62K | 0.00% | N/A | $2.02 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |